MX2024006991A - Composiciones farmaceuticas inyectables y usos de las mismas. - Google Patents

Composiciones farmaceuticas inyectables y usos de las mismas.

Info

Publication number
MX2024006991A
MX2024006991A MX2024006991A MX2024006991A MX2024006991A MX 2024006991 A MX2024006991 A MX 2024006991A MX 2024006991 A MX2024006991 A MX 2024006991A MX 2024006991 A MX2024006991 A MX 2024006991A MX 2024006991 A MX2024006991 A MX 2024006991A
Authority
MX
Mexico
Prior art keywords
injectable pharmaceutical
pharmaceutical compositions
moxidectin
microspheres
treating
Prior art date
Application number
MX2024006991A
Other languages
English (en)
Inventor
Frank Guerino
Keith Freehauf
Brian Carrillo
Colon Brenda L Valle
Christopher D Kulczar
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2024006991A publication Critical patent/MX2024006991A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica inyectable que comprende un compuesto de isoxazolina de la fórmula (I): (ver Fórmula) Fórmula (I) o una sal o N-óxido, y microesferas de moxidectina, y un método para la prevención o el tratamiento de una infestación de parásitos a través del uso de la misma.
MX2024006991A 2019-05-03 2021-11-01 Composiciones farmaceuticas inyectables y usos de las mismas. MX2024006991A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962842709P 2019-05-03 2019-05-03

Publications (1)

Publication Number Publication Date
MX2024006991A true MX2024006991A (es) 2024-06-19

Family

ID=70482684

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021013429A MX2021013429A (es) 2019-05-03 2020-05-01 Composiciones farmaceuticas inyectables y usos de las mismas.
MX2024006991A MX2024006991A (es) 2019-05-03 2021-11-01 Composiciones farmaceuticas inyectables y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021013429A MX2021013429A (es) 2019-05-03 2020-05-01 Composiciones farmaceuticas inyectables y usos de las mismas.

Country Status (14)

Country Link
US (1) US20220296564A1 (es)
EP (1) EP3962448A1 (es)
JP (1) JP7558197B2 (es)
KR (1) KR20220004158A (es)
CN (1) CN113784702A (es)
AU (1) AU2020268618A1 (es)
BR (1) BR112021021649A2 (es)
CA (1) CA3138263A1 (es)
CL (1) CL2021002865A1 (es)
CO (1) CO2021014266A2 (es)
IL (1) IL287628A (es)
MX (2) MX2021013429A (es)
PE (1) PE20220173A1 (es)
WO (1) WO2020225143A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102677903B1 (ko) * 2017-11-07 2024-06-21 인터벳 인터내셔널 비.브이. 주사가능한 이속사졸린 제약 조성물 및 그의 기생충 침입에 대한 용도
ES2973362T3 (es) * 2019-12-16 2024-06-19 Intervet Int Bv Control de parásitos en rumiantes
WO2022255463A1 (ja) * 2021-06-02 2022-12-08 日本農薬株式会社 ベンゾイミダゾール化合物又はその塩類及び該化合物を含有する犬糸状虫症防除剤並びにその使用方法
CN116236448A (zh) * 2023-03-07 2023-06-09 四川新益峰生物制药有限公司 一种高效的阿苯达唑伊维菌素预混剂分散体颗粒组方与生产工艺

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740421A (en) 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
DE69208765T2 (de) 1991-07-23 1996-09-26 American Cyanamid Co Stabile Zusammensetzungen für parenterale Verabrechung und ihre Verwendung
ES2304371T3 (es) 2000-10-10 2008-10-16 Wyeth Holdings Corporation Composiciones estables para administracion parenteral.
DK1731512T3 (en) 2004-03-05 2015-01-05 Nissan Chemical Ind Ltd Isoxazoline-substituted benzamide AND INSTRUMENTS FOR COMBATING HARMFUL ORGANISMS
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
HUE037127T2 (hu) 2007-06-27 2018-08-28 Du Pont Állati károkozó irtására szolgáló eljárás
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
JP5365807B2 (ja) 2007-11-12 2013-12-11 日産化学工業株式会社 光学活性イソキサゾリン化合物の触媒的不斉合成方法
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
CN102149695B (zh) 2008-07-09 2015-02-04 日产化学工业株式会社 异*唑啉取代的苯甲酰胺化合物的制造方法
EP2379544B1 (en) 2008-12-18 2013-10-16 Novartis AG Isoxazolines derivatives and their use as pesticide
ES2395704T3 (es) 2008-12-19 2013-02-14 Novartis Ag Derivados de isoxazolina y su uso como pesticida
JP5679102B2 (ja) 2009-08-03 2015-03-04 日産化学工業株式会社 ジヒドロイソキサゾール置換安息香酸化合物の光学活性体とジアステレオマー塩及びその製造方法
TWI487486B (zh) 2009-12-01 2015-06-11 Syngenta Participations Ag 以異唑啉衍生物為主之殺蟲化合物
EP2556060A1 (en) 2010-04-08 2013-02-13 Ah Usa 42 Llc Substituted 3,5- diphenyl-isoxazoline derivatives as insecticides and acaricides
KR102027723B1 (ko) 2010-12-27 2019-10-01 인터벳 인터내셔널 비.브이. 국소 적용 이속사졸린 제제
WO2012089623A1 (en) 2010-12-27 2012-07-05 Intervet International B.V. Topical localized isoxazoline formulation comprising glycofurol
AU2013245011B2 (en) 2012-04-04 2017-11-23 Intervet International B.V. Solid oral pharmaceutical compositions for isoxazoline compounds
WO2015048371A1 (en) 2013-09-30 2015-04-02 Zoetis Llc Long-acting spiro-isoxazoline formulations
UY36570A (es) 2015-02-26 2016-10-31 Merial Inc Formulaciones inyectables de acción prolongada que comprenden un agente activo isoxazolina, métodos y usos de las mismas
SG11201708068PA (en) 2015-04-08 2017-10-30 Merial Inc Extended release injectable formulations comprising an isoxazoline active agent, methods and uses thereof
ITUB20153652A1 (it) 2015-09-16 2017-03-16 Fatro Spa Microsfere contenenti lattoni macrociclici antielminitici
UY37137A (es) 2016-02-24 2017-09-29 Merial Inc Compuestos antiparasitarios de isoxazolina, formulaciones inyectables de acción prolongada que los comprenden, métodos y usos de los mismos
WO2018039508A1 (en) 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
WO2019012377A1 (en) 2017-07-10 2019-01-17 Basf Se MIXTURES COMPRISING AN INSECTICIDE AND A NITRIFICATION INHIBITOR SUCH AS 2- (3,4-DIMETHYL-1H-PYRAZOL-1-YL) SUCCINIC ACID (DMPSA) OR 3,4-DIMETHYL PYRAZOLIUM GLYCOLATE (DMPG)

Also Published As

Publication number Publication date
CA3138263A1 (en) 2020-11-12
JP7558197B2 (ja) 2024-09-30
WO2020225143A1 (en) 2020-11-12
CO2021014266A2 (es) 2021-10-29
US20220296564A1 (en) 2022-09-22
BR112021021649A2 (pt) 2021-12-21
PE20220173A1 (es) 2022-01-28
KR20220004158A (ko) 2022-01-11
AU2020268618A1 (en) 2021-11-04
JP2022531590A (ja) 2022-07-07
CL2021002865A1 (es) 2022-06-17
EP3962448A1 (en) 2022-03-09
IL287628A (en) 2021-12-01
CN113784702A (zh) 2021-12-10
MX2021013429A (es) 2021-12-10

Similar Documents

Publication Publication Date Title
MX2024006991A (es) Composiciones farmaceuticas inyectables y usos de las mismas.
AU2018312326A2 (en) Heterocyclic compound and use thereof
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
DOP2020000023A (es) Nuevos derivados de quinolina
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
EP4316522A3 (en) Injectable isoxazoline pharmaceutical compositions and their use against parasite infestation
UY37789A (es) Nuevos derivados de azaquinolina
PH12016500573B1 (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
MX2021004474A (es) Compuestos que contienen deuterio.
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
AU2020231934A8 (en) Compounds useful in HIV therapy
BR112018074985A2 (pt) composições antibacterianas
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112017021380A2 (pt) composto, combinação, formulação farmacêutica, método de extermínio e/ou prevenção do crescimento de um protozoário, e, uso de composto
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
MX2020006055A (es) Composiciones farmaceuticas implantables de isoxazolina y usos de las mismas.
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
BR112021018084A8 (pt) Medicamento e método para tratamento ou prevenção de complicações de diabetes usando o mesmo medicamento
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
EA201991570A1 (ru) Амидные соединения и их применение
PH12020550549A1 (en) Compositions for preventing or treating lupus